PhRMA and Private Oncology Practices Slam PBMs’ Role in 340B in Comments to FTC

Federal Trade Commission sign over entrance.
The FTC and HHS asked for stakeholder feedback on generic drug shortages, which could have implications for the 340B program.

Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not benefit patients,

Read More »

Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials

Headshots of U.S. House gang of six Representatives Spanberger, Axne, McKinley, Matsui, Katko, Johnson
Clockwise from top left, Reps. Abigail D. Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) are urging fellow House members to sign a letter urging HHS to begin 340B enforcement actions against drug companies.

Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on prescription drugs.”

Read More »

NACHC Tells Merck its 340B Contract Pharmacy Policy for Health Centers Can Be Explained by “Only Greed”

Merck corporate campus outdoor sign and building
NACHC's president and CEO told her counterpart at Merck the company's decision to impose conditions on 340B on health centers, but not on other grantee covered entities, "cannot be explained by logic, only greed.”

The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”

Merck’s April 28 decision to extend its restrictions on 340B pricing

Read More »

Novartis and United Therapeutics File Briefs in Appeals Court in 340B Contract Pharmacy Lawsuits

U.S. federal appeals court Washington, D.C. building
Novartis and United Therapeutics filed briefs last night in a federal appeals court in Washington, D.C., backing their right to impose conditions on 340B sales.

Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to 340B drug

Read More »

News Alert

Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions

Exelixis wordmark building-mounted sign
California-based biopharmaceutical company Exelixis is the 17th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.

The company, a specialty manufacturer with two high-priced drug products on the market, announced its policy in email notices to covered

Read More »

AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims

screenshot of HRSA 340B administrative dispute resolution web page
AstraZeneca and Sanofi asked a 340B administrative dispute resolution panel to dismiss NACHC’s claims its members are being overcharged due to the companies’ 340B contract pharmacies policies.

Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales when health

Read More »

GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

three Nucala injectible drug tubes
GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Drug wholesaler AmerisourceBergen recently posted a

Read More »

Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges

e5 Pharma wordmark
e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021.

Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Florida-based e5

Read More »

OptumRx Says Providers Can’t Share 340B Claims Data Without its Consent

Optum wordmark building-mounted sign
OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers.

Pharmacy care services company OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing.

OptumRx—a part of information and health services business

Read More »

PhRMA-funded Study Faults 340B Hospitals’ Financial Aid and Debt Collection Policies

A hospital stay invoice
The AHA sharply criticized a new PhRMA-funded study that says many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions."

Many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions, including but not limited to, liens, foreclosures, and civil actions when patients fail to pay bills,” a pharmaceutical-industry funded study released

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report